I-MAB Biopharma Co., Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC 2023-07-05 20:00
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022 2022-08-30 18:00
I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board 2020-12-01 21:00
I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with Cytokine Release Syndrome 2020-05-28 04:05
I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center 2019-04-08 09:01
I-Mab Biopharma and Bio-Cancer Treatment International Announce Intention for Collaboration on Arginine Depletion Therapy and Biomarker Study, with Plans for I-Mab to Establish a Translational Medicine Lab in Hong Kong 2019-02-01 17:46
MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210 2018-11-16 05:01
I-Mab Wins Frost & Sullivan "2018 Best R&D Innovator Award (Biopharma Category)" 2018-09-19 15:33
I-Mab Biopharma Announces New CFO 2018-08-01 08:44
I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies 2018-07-26 21:30
I-Mab Successfully Raised USD 220 Million in Series C Funding 2018-06-29 18:36
I-Mab Biopharma Partners with MorphoSys on Cancer Investigational Medicine 2017-12-01 15:55
1